Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 212123
Company: AVID RADIOPHARMS INC
Company: AVID RADIOPHARMS INC
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
TAUVID | FLORTAUCIPIR F-18 | 30ML (8.1-51mCi/ML) | SOLUTION;INTRAVENOUS | Discontinued | None | Yes | No |
TAUVID | FLORTAUCIPIR F-18 | 50ML (8.1-51mCi/ML) | SOLUTION;INTRAVENOUS | Discontinued | None | Yes | No |
TAUVID | FLORTAUCIPIR F-18 | 50ML (8.1-100mCi/ML) | SOLUTION;INTRAVENOUS | Prescription | None | Yes | Yes |
TAUVID | FLORTAUCIPIR F-18 | 100ML (8.1-100mCi/ML) | SOLUTION;INTRAVENOUS | Prescription | None | Yes | Yes |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
05/28/2020 | ORIG-1 | Approval | Type 1 - New Molecular Entity | PRIORITY |
Label (PDF)
Letter (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212123s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/212123Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212123Orig1s000TOC.cfm |
Supplements
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
---|---|---|---|---|---|
02/05/2024 | SUPPL-31 | Labeling |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212123s031lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/212123Orig1s031ltr.pdf | |
07/01/2022 | SUPPL-4 | Manufacturing (CMC)-Manufacturing Process |
Label (PDF)
|
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212123Orig1s004lbl.pdf |
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
---|---|---|---|---|---|
02/05/2024 | SUPPL-31 | Labeling | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212123s031lbl.pdf | |
07/01/2022 | SUPPL-4 | Manufacturing (CMC)-Manufacturing Process | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212123Orig1s004lbl.pdf | |
05/28/2020 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212123s000lbl.pdf |